Reminder - The Singapore Fund (SGF) Goes Ex-Dividend Soon

Looking at the universe of stocks we cover at Dividend Channel, on 9/18/14, The Singapore Fund (SGF) will trade ex-dividend, for its quarterly dividend of $0.22, payable on 9/30/14. As a percentage of SGF's recent stock price of $12.81, this dividend works out to approximately 1.72%, so look for shares of The Singapore Fund to trade 1.72% lower — all else being equal — when SGF shares open for trading on 9/18/14.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for SGF, showing historical dividends prior to the most recent $0.22 declared by The Singapore Fund:

SGF+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from SGF is likely to continue, and whether the current estimated yield of 6.87% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of SGF shares, versus its 200 day moving average:

The Singapore Fund 200 Day Moving Average Chart

Looking at the chart above, SGF's low point in its 52 week range is $11.79 per share, with $13.92 as the 52 week high point — that compares with a last trade of $12.81.

In Tuesday trading, The Singapore Fund shares are currently off about 0.7% on the day.

More from Stocks

Banks Prepare to Up Shareholder Payouts By $30 Billion

Banks Prepare to Up Shareholder Payouts By $30 Billion

Starbucks Just Revealed Some of the Most Worrying Data in Its History

Starbucks Just Revealed Some of the Most Worrying Data in Its History

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Biotech Firm Sarepta Surges 40% on Positive Test Results

Biotech Firm Sarepta Surges 40% on Positive Test Results